Table 1.
Description of Canadian Drugstore and Hospital (CDH) purchases and potential dollar savings from July 2016 to June 2018 for all provinces
| CDH Purchases | Units Purchased | Price Per Unit | Average Discounted Price (%) | Average Realized Savings through use of biosimilar | Unrealized Savings | Overall savings realized (%) | |
|---|---|---|---|---|---|---|---|
| Lantus® | $ 141,135,286 | 7,328,068 | $ 19.26 |
$ 4.07 (21.1%) |
$ 2,519,961 | $29,825,236 | 7.8% |
| Basaglar® | $ 9,402,061 | 619,155 | $ 15.19 | ||||
| Neupogen® | $ 204,152,590 | 1,033,508 | $ 197.53 |
$ 35.17 (17.8%) |
$ 13,443,873 | $36,348,476 | 27.0% |
| Grastofil® | $ 62,061,576 | 382,254 | $ 162.36 | ||||
| Remicade® | $ 2,192,819,808 | 2,190,467 | $ 1001.07 |
$ 448.53 (44.8%) |
$ 30,199,524 | $982,490,164 | 3.0% |
| Inflectra® | $ 37,202,503 | 67,330 | $ 552.54 | ||||
| TOTAL | $ 46,163,358 | $1,048,663,876 | 4.2% |
All dollar figures are in Canadian dollars
Estimates of realized and unrealized savings are based on the average discounted price amongst all provinces
Unrealized savings is calculated as the average price difference between the originator and biosimilar amongst all provinces, multiplied by the number of originator units sold